Efficacy of Automated Insulin Therapy Early Initiated After Diagnosis on Blood Glucose Control in Children and Adolescents With Type 1 Diabetes
Recruiting
N/AInterventional Study
Diabetes
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
2 – 18
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
112 (estimated)
Sponsor
University Hospital, Montpellier · Other
Who this trial is looking for
This trial is looking for children and adolescents aged 2 to 17 with type 1 diabetes to see if starting an automated insulin treatment early can help control their blood sugar better than standard injections or pumps. Participants will use a specific app and sensor to track their glucose levels during the study.
Are You a Good Fit for This Trial?
You may be able to join if
I am between 2 and 17.9 years old.
I have been diagnosed with type 1 diabetes for at least 3 months.
I have at least one positive test for diabetes-related auto-antibodies.
I am using multiple daily insulin injections or an insulin pump.
I or my guardians can count carbohydrates.
I have a smartphone that supports the Dexcom G6 app.
I am willing to use the Dexcom G6 sensor and app throughout the study.
You may not be able to join if
One of my parents or guardians does not want to participate.
I have another chronic disease affecting my blood sugar.
I am already using an automated insulin delivery system.
I have an allergy to the device adhesives.
I have trouble seeing or hearing the device alerts.
I have cognitive or psychological issues affecting my ability to participate.
I am enrolled in another clinical trial or took an unapproved drug recently.
I cannot attend all scheduled visits.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
The main objective is to assess whether hybrid closed-loop (HCL) insulin delivery initiated early after diagnosis of Type 1 diabetes (T1D) allows a better efficacy on glucose control than conventional standard insulin therapy with multiple daily insulin injections (MDI) or insulin pumps after one year of use.
The secondary objectives are to assess whether HCL initiated early after diagnosis of T1…
The main objective is to assess whether hybrid closed-loop (HCL) insulin delivery initiated early after diagnosis of Type 1 diabetes (T1D) allows a better efficacy on glucose control than conventional standard insulin therapy with multiple daily insulin injections (MDI) or insulin pumps after one year of use.
The secondary objectives are to assess whether HCL initiated early after diagnosis of T1D allows: (1) Higher time spent with glucose level in the near-normal range, (2) Lower time spent in hypoglycemia and hyperglycemia, (3) Lower glucose variability, (4) Lower perceived burden of diabetes management, (5) Better preserved endogenous insulin secretion, all the above after one year of use, (6) Lower occurrence of interventions for hypoglycemia, versus conventional standard insulin therapy with MDI or insulin pump.
An optional 1-year extension aims at assessing: (1) Sustainability of above mentioned parameters over a second year of HCL use in the group who started HCL early after diagnosis, (2) Efficacy on glucose control according to the above mentioned parameters when HCL is initiated early after diagnosis vs. after 1 year in the control group of the randomized phase.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Aged between 2 and 17.9 years
* Diagnosis of type 1 diabetes since at least 3 months and up to 6 months based upon WHO criteria
* Identification of at least one positive plasma auto-antibody among anti-GAD, anti-IA2, anti-ZnT8 and anti-insulin
* Treatment by multiple-daily ins…
Inclusion Criteria:
* Aged between 2 and 17.9 years
* Diagnosis of type 1 diabetes since at least 3 months and up to 6 months based upon WHO criteria
* Identification of at least one positive plasma auto-antibody among anti-GAD, anti-IA2, anti-ZnT8 and anti-insulin
* Treatment by multiple-daily insulin injections or insulin pump. An insulin pump with a function of stopping the pump in case of predicted hypoglycaemia is allowed.
* Patient and/or parents/guardians trained in carbohydrate counting
* Patient and/or parents/guardians must have a smartphone that supports the Dexcom G6 app download and participants must be willing to use Dexcom G6 sensor and app throughout the study
Exclusion Criteria:
* Unwillingness of one parent or the legally responsible party to participate in insulin treatment
* Any associated chronic disease or therapy (except insulin or L thyroxin at stable dose) affecting glucose metabolism
* Therapy by automated insulin delivery using an insulin pump connected to continuous glucose monitoring sensor with a control algorithm (hybrid closed-loop system)
* Cutaneous allergy or contact dermatitis to device (CGM or pod) adhesives
* Insufficient vision and/or hearing to recognise all the functions of the Omnipod 5 system, including alerts, alarms and reminders in accordance with the instructions of utilization
* Impaired cognitive or psychological abilities of the patient and/or his/her parents or the legally responsible party which may result in defective adherence to study procedures
* Active enrolment in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date
* Subject who is in a dependency or employment with the sponsor or the investigator
* No signed informed consent form by the patient and his/her parents/legally responsible party
* Subjects unable to attend all scheduled visits and to comply with all trial procedures
* Law protected or deprived of liberty subject
* Pregnant and breastfeeding women
* Subjects no covered by public health insurance
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
